Observational Study on Diet, Gut Bacteria, and Chemotherapy for Pancreatic Cancer
This observational study aims to understand how your diet and the bacteria in your gut (fecal microbiome) might affect how well chemotherapy works for pancreatic cancer. Researchers are looking at patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (a type of pancreatic cancer that can be removed by surgery). You would complete a dietary survey and provide a stool sample. The main goal is to see if there's a link between your diet, your gut bacteria, and how your cancer responds to chemotherapy. This study is currently unclear on its recruitment status and plans to enroll 87 participants.
- Study design
- This is an observational study involving 87 participants. It is not testing a new treatment but rather observing existing patterns.
- What's involved
- You would complete a dietary survey and provide a fecal (stool) sample during the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your fecal microbiome will be measured through study completion, which is an average of two years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
At a glance
Conditions
NCT06595160
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Mihir M Shah · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Fecal Microbiome Alpha DiversityThrough study completion, an average of two years
Continuous variables will be presented as median with interquartile range and categorical variables will be presented as frequencies. Univariate logistic regression will be used to compare alpha diversity (mean inverse Simpson index) and relative abundance of operational taxonomic units up to species level in PDAC patients with and without major pathological response to neoadjuvant chemotherapy. Multivariable logistic regression analyses will be performed to identify significant factors associated with major pathological response after adjusting for age, gender, stage at presentation, and type of neoadjuvant chemotherapy and other factors based on univariate analyses or clinical significance.